Cover Image

Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis

Hereditary transthyretin-mediated amyloidosis is a rapidly progressive, heterogeneous disease caused by the accumulation of misfolded transthyretin protein as amyloid fibrils at multiple sites, and is characterized by peripheral sensorimotor neuropathy, autonomic neuropathy and/or cardiomyopathy. Cu...

Full description

Saved in:
Bibliographic Details
Main Authors: Kristen, Arnt (Author) , Ajroud-Driss, Senda (Author) , Conceição, Isabel (Author) , Gorevic, Peter (Author) , Kyriakides, Theodoros (Author) , Obici, Laura (Author)
Format: Article (Journal)
Language:English
Published: 27 Nov 2018
In: Neurodegenerative disease management
Year: 2018, Volume: 9, Issue: 1, Pages: 5-23
ISSN:1758-2024
DOI:10.2217/nmt-2018-0033
Online Access:Verlag, Volltext: https://doi.org/10.2217/nmt-2018-0033
Verlag: https://www.futuremedicine.com/doi/10.2217/nmt-2018-0033
Get full text
Author Notes:Arnt V. Kristen, Senda Ajroud-Driss, Isabel Conceição, Peter Gorevic, Theodoros Kyriakides, & Laura Obici
Description
Summary:Hereditary transthyretin-mediated amyloidosis is a rapidly progressive, heterogeneous disease caused by the accumulation of misfolded transthyretin protein as amyloid fibrils at multiple sites, and is characterized by peripheral sensorimotor neuropathy, autonomic neuropathy and/or cardiomyopathy. Current treatment options have limited efficacy and often do not prevent disease progression. Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein. In Phase II, III and long-term extension studies in patients with hereditary transthyretin-mediated amyloidosis, patisiran has consistently slowed or improved progression of neuropathy. In addition, the Phase III trial demonstrated significant improvements in quality of life measures and indicators of cardiomyopathy. Here, we highlight efficacy and safety data from the patisiran clinical trial programme.
Item Description:Gesehen am 30.10.2019
Physical Description:Online Resource
ISSN:1758-2024
DOI:10.2217/nmt-2018-0033

Similar Items